175 related articles for article (PubMed ID: 11292480)
1. A C3 convertase assay for nephritic factor functional activity.
Jelezarova E; Schlumberger M; Sadallah S; Späth PJ; Schifferli JA; Lutz HU
J Immunol Methods; 2001 May; 251(1-2):45-52. PubMed ID: 11292480
[TBL] [Abstract][Full Text] [Related]
2. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
3. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
4. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
5. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
6. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
7. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
8. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
9. Further evidence for the antibody nature of C3 nephritic factor (C3NeF).
Daha MR; van Es LA
J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217
[TBL] [Abstract][Full Text] [Related]
10. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
[TBL] [Abstract][Full Text] [Related]
11. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
Jelezarova E; Vogt A; Lutz HU
Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
[TBL] [Abstract][Full Text] [Related]
12. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
14. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).
Ohi H; Watanabe S; Fujita T; Yasugi T
Clin Exp Immunol; 1992 Sep; 89(3):479-84. PubMed ID: 1516262
[TBL] [Abstract][Full Text] [Related]
15. Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase.
Spitzer RE; Stitzel AE; Tsokos GC
Clin Immunol Immunopathol; 1990 Oct; 57(1):19-31. PubMed ID: 2394034
[TBL] [Abstract][Full Text] [Related]
16. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
18. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis.
Spitzer RE; Stitzel AE; Tsokos GC
Clin Immunol Immunopathol; 1990 Oct; 57(1):10-8. PubMed ID: 1697516
[TBL] [Abstract][Full Text] [Related]
19. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
20. IgG naturally occurring antibodies stabilize and promote the generation of the alternative complement pathway C3 convertase.
Jelezarova E; Lutz HU
Mol Immunol; 2005 Jul; 42(11):1393-403. PubMed ID: 15950735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]